Identification and characterization of immunodominant B-cell epitope of the C-terminus of protective antigen of Bacillus anthracis

Molecular Immunology

Volumn 46, Issue 10, 2009, Pages 2107-2115

  Kaur, Manpreet ^a   Chug, Hema ^b   Singh, Harpreet ^a   Chandra, Subhash ^c   Mishra, Manish ^a   Sharma, Meenakshi ^a   Bhatnagar, Rakesh ^a  

^a JAWAHARLAL NEHRU UNIVERSITY   (India)

^b Molecular Biology Programme   (Germany)

^c Animal Health Diagnostic Center   (United States)

Author keywords

B cell epitope; Immunodominant; Lethal toxin neutralizing antibodies; Protection

Indexed keywords

ANTHRAX TOXIN; ANTHRAX VACCINE; EPITOPE; GAMMA INTERFERON; IMMUNODOMINANT EPITOPE I[604-622] VACCINE; IMMUNODOMINANT EPITOPE II[626-676] VACCINE; IMMUNODOMINANT EPITOPE III[707-723] VACCINE; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 4; LETHAL TOXIN; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BACILLUS ANTHRACIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISSOCIATION CONSTANT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; MACROPHAGE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SURVIVAL TIME; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; ANTIBODY FORMATION; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; CYTOKINES; EPITOPES, B-LYMPHOCYTE; IMMUNE SERA; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN G; KINETICS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDES; SURVIVAL ANALYSIS; T-LYMPHOCYTES, HELPER-INDUCER; VACCINATION;

BACILLUS ANTHRACIS; MUS;

EID: 67349091654     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.12.031     Document Type: Article

References (55)

1. Brahmbhatt T.N., Darnell S.C., Carvalho H.M., Sanz P., Kang T.J., Bull R.L., Rasmussen S.B., Cross A.S., and O'Brien A.D. Recombinant exosporium protein BclA of Bacillus anthracis is effective as a booster for mice primed with suboptimal amounts of protective antigen. Infect. Immun. 75 (2007) 5240-5247
2. Brey R.N. Molecular basis for improved anthrax vaccines. Adv. Drug Deliv. Rev. 57 (2005) 1266-1292
3. Brian M.P., Liner A.L., Park S., Leppla S.H., Mateczun A., and Galloway D.R. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69 (2001) 4509-4515
4. Brossier F., Sirard J.C., Guidi-Rontani C., Duflot E., and Mock M. Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect. Immun. 67 (1999) 964-967
5. Brossier F., Weber-Levy M., Mock M., and Sirard J.C. Protective antigen mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis. Infect. Immun. 68 (2000) 5731-5734
6. Chauhan V., Singh A., Waheed S.M., Singh S., and Bhatnagar R. Constitutive expression of protective antigen gene of Bacillus anthracis in Escherichia coli. Biochem. Biophys. Res. Commun. 283 (2001) 308-315
7. Dong X.N., Qi Y., Ying J., Chen X., and Chen Y.H. Candidate peptide vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2. Vaccine 24 (2006) 426-434
8. El Kasmi K.C., and Muller C.P. New strategies for closing the gap of measles susceptibility in infants: towards vaccines compatible with current vaccination schedules. Vaccine 19 (2001) 2238-2244
9. Elliott J.L., Mogridge J., and Collier R.J. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 39 (2000) 6706-6713
10. + T-cell peptide epitope-based vaccine for infectious mononucleosis. J. Virol. 82 (2008) 1448-1457
11. EL-Manzalawy Y., Dobbs D., and Honavar V. Predicting linear B-cell epitopes using string kernels. J. Mol. Recognit. 21 (2008) 243-255
12. Escuyer V., and Collier R.J. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59 (1991) 3381-3386
13. Fernandez I.M., Snijders A., Benaissa-Trouw B.J., Harmsen M., Snippe H., and Kraaijeveld C.A. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus. J. Virol. 67 (1993) 5843-5848
14. Flick-Smith H.C., Walker N.J., Gibson P., Bullifent H., Hayward S., Miller J., Titball R.W., and Williamson E.D. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun. 70 (2002) 1653-1656
15. Friguet B., Chaffotte A.F., Djavadi-Ohaniance L., and Goldberg M.E. Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J. Immunol. Methods 77 (1985) 305-319
16. Gahery H., Daniel N., Charmeteau B., Ourth L., Jackson A., Andrieu M., Choppin J., Salmon D., Pialoux G., and Guillet J.G. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22 (2006) 684-694
17. Gu M.L., Leppla S.H., and Klinman D.M. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17 (1999) 340-344
18. Gupta P., Batra S., Chopra A.P., Singh Y., and Bhatnagar R. Expression and purification of the recombinant lethal factor of Bacillus anthracis. Infect. Immun. 66 (1998) 66862-66865
19. Hsu S., Chargelegue D., Obeid O., and Steward M. Synergistic effect of immunization a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. J. Gen. Virol. 80 (1999) 1401-1405
20. Jernigan J.A., Stephens D.S., Ashford D.A., Omenaca C., Topiel M.S., Galbraith M., Tapper M., Fisk T.L., Zaki S., Popovic T., Meyer R.F., Quinn C.P., Harper S.A., Fridkin S.K., Sejvar J.J., Shepard C.W., McConnell M., Guarner J., Shieh W.J., Malecki J.M., Gerberding J.L., Hughes J.M., Perkins B.A., and members of the Anthrax Bioterrorism Investigation Team. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7 (2001) 933-944
21. Johansen P., Men Y., Merkle H.P., and Gander B. Revisiting PLA/PLGA microspheres: an analysis of their potential in parenteral vaccination. Eur. J. Pharm. Biopharm. 50 (2000) 129-146
22. Khan A.A., Babu J.P., Gupta G., and Rao D.N. Identifying B and T cell epitopes and studying humoral, mucosal and cellular immune response of V antigen of Yersinia pestis. Vaccine 26 (2008) 316-332
23. Kieber-Emmons T., Luo P., Qiu J., Chang T.Y., Insung O., Blaszczyk-Thurin M., and Steplewski Z. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat. Biotechnol. 17 (1999) 660-665
24. Kublin J.G., Lowitt M.H., Hamilton R.G., Oliveira G.A., Nardin E.H., Nussenzweig R.S., Schmeckpeper B.J., Diggs C.L., Bodison S.A., and Edelman R. Delayed-type hypersensitivity in volunteers immunized with a synthetic multi-antigen peptide vaccine (PfCS-MAP1NYU) against Plasmodium falciparum sporozoites. Vaccine 20 (2002) 1853-1861
25. Laffly E., Danjou L., Condemine F., Vidal D., Drouet E., Lefranc M.P., Bottex C., and Thullier P. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob. Agents Chemother. 49 (2005) 3414-3420
26. Leppla S.H. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. U.S.A. 79 (1982) 3162-3166
27. Leppla S.H., Robbins J.B., Schneerson R., and Shiloach J. Development of an improved vaccine for anthrax. J. Clin. Investig. 110 (2002) 141-144
28. Li X., Yang X., Jiang Y., and Liu J. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice. Int. Immunol. 17 (2005) 1293-1302
29. Little S.F., and Ivins B.E. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect. 2 (1999) 131-139
30. Little S.F., Leppla S.H., and Cora E. Production and characterization of monoclonal antibodies to the protective antigen of Bacillus anthracis toxin. Infect. Immun. 56 (1988) 1807-1813
31. Little S.F., Novak J.M., Lowe R.J., Leppla S.H., Singh Y., Klimpel K.R., Lidgerding B.C., and Friedlander A.M. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142 (1996) 707-715
32. Liu G.J., Yang L.M., Wang J.H., Zhang G.H., Chen X.M., and Zheng Y.T. Immune responses to six synthetic peptides of capsid protein with sera from HIV-1 infected individuals. Cell Mol. Immunol. 2 (2005) 289-293
33. McBride B.W., Mogg A., Telfer J.L., Lever M.S., Miller J., Turnbull P.C.B., and Baille L. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16 (1998) 810-818
34. Mock M., and Fouet A. Anthrax. Annu. Rev. Microbiol. 55 (2001) 647-671
35. Musson J.A., Walker N., Flick-Smith H., Williamson E.D., and Robinson J.H. Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis. J. Biol. Chem. 278 (2003) 52425-52431
36. Nardin E.H., Oliveira G.A., Calvo-Calle J.M., Castro Z.R., Nussenzweig R.S., Schmeckpeper B., Hall B.F., Diggs C., Bodison S., and Edelman R. Synthetic malaria peptide vaccine e high levels of antibodies in vaccinees of defined HLA genotypes. J. Infect. Dis. 182 (2000) 1486-1496
37. Ostankovitch M., Guichard G., Connan F., Muller S., Chaboissier A., Hoebeke J., Choppin J., Briand J.P., and Guillet J.G. A partially modified retro-inverso pseudopeptide modulates the cytokine profile of CTL specific for an influenza virus epitope. J. Immunol. 161 (1998) 200-208
38. Park Y.S., Lee J.H., Hung C.F., Wu T.C., and Kim T.W. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant. Infect. Immun. 76 (2008) 1952-1959
39. Peng W., Hou Q., Xia Z., Chen D., Li N., Sun Y., and Qiu H. Identification of a conserved linear B-cell epitope at the N-terminus of the E2 glycoprotein of Classical swine fever virus by phage-displayed random peptide library. Virus Res. 35 (2008) 267-272
40. Petosa C., Collier R.J., Klimpel K.R., Leppla S.H., and Liddington R.C. Crystal structure of the anthrax toxin protective antigen. Nature 385 (1997) 833-838
41. Pitt M.L., Little S., Ivins B.E., Fellows P., Boles J., Barth J., Hewetson J., and Friedlander A.M. In vitro correlate of immunity in an animal model of inhalational anthrax. J. Appl. Microbiol. 87 (1999) 304
42. Pullen G.R., Fitzgerald M.G., and Hosking C.S. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 86 (1986) 83-87
43. Reddy K.J., Banapour B., Anderson D.E., Lee S.H., Marquez J.P., Carlos M.P., and Torres J.V. Induction of immune responses against human papillomaviruses by hypervariable epitope constructs. Immunology 112 (2004) 321-327
44. Reuveny S., White M.D., Adar Y.Y., Kafri Y., Altboum Z., Gozes Y., Kobiler D., Shafferman A., and Velan B. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69 (2001) 2888-2893
45. Ribeiro S., Rijpkemab S.G., Durrani Z., and Florence A.T. PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice. Int. J. Pharm. 331 (2007) 228-232
46. Sabhnani L., Manocha M., Sridevi K., Shashikiran D., Rayanade R., and Rao D.N. Developing subunit immunogens using B and T cell epitopes and their constructs derived from the F1 antigen of Yersinia pestis using novel delivery vehicles. FEMS Immunol. Med. Microbiol. 38 (2003) 215-229
47. Saha, S., Raghava, G.P.S., 2004. BcePRED: prediction of continuous B-Cell epitopes in antigenic sequences using physico-chemical properties. In: Nicosia, G., Cutello, V., Bentley, P.J., Timis, J. (Eds.), ICARIS, LNCS 3239, pp. 197-204.
48. Selo I., Clement G., Bernard H., Chatel J., Creminon C., Peltre G., and Wal J. Allergy to bovine beta lactoglobulin: specificity of human IgE to tryptic peptides. Clin. Exp. Allergy 29 (1999) 1055-1063
49. Singh M., Kazzaz J., Ugozzoli M., Chesko J., and O'Hagan D.T. Charged polylactide-co-glycolide microparticles as antigen delivery systems. Expert. Opin. Biol. Ther. 4 (2004) 483-491
50. Stanley J.L., and Smith H. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 26 (1961) 49-63
51. Sundaram R., Lynch M.P., Rawale S.V., Sun Y., Kazanji M., and Kaumaya P.T. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J. Biol. Chem. 279 (2004) 24141-24151
52. Tripathi V., Chitralekha K.T., Bakshi A.R., Tomar D., Deshmukh R.A., Baig M.A., and Rao D.N. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery. Vaccine 24 (2006) 3279-3289
53. Varughese M., Teixeira A.V., Liu S., and Leppla S.H. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect. Immun. 67 (1999) 1860-1865
54. Vitale G., Pellizzari R., Recchi C., Napolitani G., Mock M., and Montecucco C. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248 (1998) 706-711
55. Xiao Y., Lu Y., and Chen Y.H. Epitope-vaccine as a new strategy against HIV-1 mutation. Immunol. Lett. 77 (2001) 3-6